[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

92

1 question. You'll see these repeated. In a sense it
2 illustrates how these groups probably will have to
3 interact closely with one another.
4 Now, the next issue, as you well know, are
5 what the immune correlates of protection are. We
6 don't know what they are at the present time. We
7 assume that -- and I've heard it said today that the
8 immunity that is generated against this virus probably
9 does not indicate that there are protective forces in
10 already infected individuals.
11 However, I believe that should be
12 questioned. It should be questioned, in particular,
13 in long-term survivors of HIV infection. Are there
14 immune functions or pseudo immune functions that we
15 should identify in such individuals that might be of
16 benefit in various types of vaccine design?
17 Another is selective activation of certain
18 types of immune responses. You heard someone mention
19 today individuals that are repeatedly exposed to HIV
20 infection and do not seroconvert. Do they have a form
21 of immunity that is protecting them from that type of
22 infection? And if so, what is it?
NEAL R. GROSS
COURT REPORTERS ND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]